Trial Profile
A Randomized Phase I/II Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Metastatic Pancreatic Cancer at First Line Therapy
Status:
Suspended
Phase of Trial:
Phase I/II
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs ABTL 0812 (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Acronyms Pancreatic
- Sponsors Ability Pharmaceuticals
- 20 Feb 2023 Planned End Date changed from 30 Mar 2023 to 26 Apr 2024.
- 20 Feb 2023 Planned primary completion date changed from 30 Mar 2022 to 26 Apr 2023.
- 20 Feb 2023 Status changed from not yet recruiting to suspended.